U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19NO3.ClH
Molecular Weight 273.756
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HA-242

SMILES

Cl.COCCCNCC1COC2=C(O1)C=CC=C2

InChI

InChIKey=ZFKJIMJKFOYFAL-UHFFFAOYSA-N
InChI=1S/C13H19NO3.ClH/c1-15-8-4-7-14-9-11-10-16-12-5-2-3-6-13(12)17-11;/h2-3,5-6,11,14H,4,7-10H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H19NO3
Molecular Weight 237.2949
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://journals.co.za/docserver/fulltext/savet/34/3/3101.pdf?expires=1481264914&id=id&accname=guest&checksum=0303CCDDD5B9B7E6FBAC76070B74B0C0

HA-242, a benzodioxan derivative, is a muscle relaxant. It can be used for the treatment of central nervous muscular spasticity. Was marketed under the name Quiloflex. Quiloflex (HA-242) is a reflex inhibitor used in human medicine for the symptomatic treatment of spasticity due to pyramidal tract lesions. Quiloflex was also used for casting cattle and horses, and although well tolerated at a dosage of 1-8 mg/kg body wt. in cattle, it was unsuitable for use in this species as the onset of relaxation was slow and the sedation prolonged. A dosage of 6 mg/kg i/m in horses gave relaxation suitable for surgery in 30 min.

Originator

Curator's Comment: In 1959 Klupp & Streller reported on the muscle relaxant effect of 2-(3'- methoxypropylaminomethyl)-1 :4-benzodioxane (HA-242)

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Quiloflex

Approved Use

Quiloflex is a reflex inhibitor used in human medicine for the symptomatic treatment of spasticity due to pyramidal tract lesions.
Primary
Quiloflex

Approved Use

Muscle Spasticity therapy, Paralysis therapy
PubMed

PubMed

TitleDatePubMed
[Treatment of central nervous muscular spasticity with a benzodioxan derivative (Quiloflex)].
1960 Dec 23

Sample Use Guides

Cattle and horses: A dosage of 6 mg/kg i/m in horses gave relaxation suitable for surgery in 30 min.
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:20:41 GMT 2023
Edited
by admin
on Sat Dec 16 08:20:41 GMT 2023
Record UNII
642H581IUJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HA-242
Common Name English
1,4-BENZODIOXAN-2-METHYLAMINE, N-(3-METHOXYPROPYL)-, HYDROCHLORIDE
Systematic Name English
QUILOFLEX
Brand Name English
1,4-BENZODIOXIN-2-METHANAMINE, 2,3-DIHYDRO-N-(3-METHOXYPROPYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
642H581IUJ
Created by admin on Sat Dec 16 08:20:41 GMT 2023 , Edited by admin on Sat Dec 16 08:20:41 GMT 2023
PRIMARY
PUBCHEM
16827
Created by admin on Sat Dec 16 08:20:41 GMT 2023 , Edited by admin on Sat Dec 16 08:20:41 GMT 2023
PRIMARY
CAS
2307-81-5
Created by admin on Sat Dec 16 08:20:41 GMT 2023 , Edited by admin on Sat Dec 16 08:20:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID40945749
Created by admin on Sat Dec 16 08:20:41 GMT 2023 , Edited by admin on Sat Dec 16 08:20:41 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY